Beta Drugs Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Beta Drugs.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 18.4% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Geen updates
Recent updates
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Beta Drugs onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2024 | 2,957 | 364 | 193 | 309 | N/A |
12/31/2023 | 2,759 | 356 | 153 | 293 | N/A |
9/30/2023 | 2,560 | 348 | 113 | 277 | N/A |
6/30/2023 | 2,416 | 327 | 83 | 255 | N/A |
3/31/2023 | 2,271 | 307 | 52 | 234 | N/A |
12/31/2022 | 2,176 | 298 | N/A | N/A | N/A |
9/30/2022 | 2,081 | 289 | 41 | 265 | N/A |
6/30/2022 | 1,960 | 269 | 72 | 281 | N/A |
3/31/2022 | 1,838 | 248 | 102 | 296 | N/A |
12/31/2021 | 1,683 | 216 | N/A | N/A | N/A |
9/30/2021 | 1,528 | 183 | 117 | 218 | N/A |
6/30/2021 | 1,345 | 150 | 123 | 202 | N/A |
3/31/2021 | 1,161 | 117 | 128 | 186 | N/A |
12/31/2020 | 1,058 | 106 | N/A | N/A | N/A |
9/30/2020 | 956 | 95 | 21 | 138 | N/A |
6/30/2020 | 932 | 94 | -24 | 111 | N/A |
3/31/2020 | 908 | 94 | -69 | 84 | N/A |
9/30/2019 | 832 | 97 | N/A | N/A | N/A |
6/30/2019 | 746 | 89 | N/A | N/A | N/A |
3/31/2019 | 659 | 80 | -206 | 1 | N/A |
3/31/2018 | 506 | 68 | 88 | 171 | N/A |
3/31/2017 | 417 | 43 | N/A | 47 | N/A |
3/31/2016 | 264 | 11 | N/A | -4 | N/A |
3/31/2015 | 3 | -1 | N/A | 14 | N/A |
3/31/2014 | 14 | 0 | N/A | 2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if BETA's forecast earnings growth is above the savings rate (6.7%).
Winst versus markt: Insufficient data to determine if BETA's earnings are forecast to grow faster than the Indian market
Hoge groeiwinsten: Insufficient data to determine if BETA's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if BETA's revenue is forecast to grow faster than the Indian market.
Hoge groei-inkomsten: Insufficient data to determine if BETA's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if BETA's Return on Equity is forecast to be high in 3 years time